Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status approved; investigational
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
UNII LR24G6354G
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Balance disorder17.02.02.007; 08.01.03.0810.000414%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Deep vein thrombosis24.01.02.0030.000504%Not Available
Malignant neoplasm progression16.16.01.0050.010801%Not Available
Lymphatic disorder01.09.01.003--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Hepatic cancer metastatic16.07.02.002; 09.04.02.006--Not Available
Peripheral sensorimotor neuropathy17.09.03.009--Not Available
Chronic inflammatory demyelinating polyradiculoneuropathy17.09.04.004; 10.04.10.0040.000112%Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000448%Not Available
Hot flush21.02.02.001; 24.03.01.005; 08.01.03.027--
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder15.06.01.006; 10.04.04.026--Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000168%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Mucosal haemorrhage24.07.01.011; 08.01.06.0050.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.002048%
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Demyelinating polyneuropathy17.09.04.003; 10.04.10.007--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.000616%
Bone marrow failure01.03.03.0050.000224%
Cytopenia01.03.03.0120.000112%Not Available
Oral herpes11.05.02.005; 07.05.07.002--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages